Description

1. Product Description 

Cargutocin (CAS 33605-67-3) is a synthetic peptide analogue of oxytocin, designed to mimic and enhance the physiological effects of oxytocin on the uterus. Oxytocin, a well-characterized neuropeptide hormone, is known for its central role in labor induction, parturition, lactation, and reproductive behavior. By targeting the oxytocin receptor (OXTR), Cargutocin promotes sustained uterine smooth muscle contraction, making it a valuable tool in reproductive biology and obstetric pharmacology research.

Background

Oxytocin analogues have long been investigated for their ability to modulate uterine contractility and assist in the management of parturition and postpartum uterine tone. Unlike natural oxytocin, synthetic analogues such as Cargutocin exhibit enhanced stability, prolonged receptor activation, and improved resistance to enzymatic degradation, allowing more controlled research studies in both in vitro and in vivo experimental systems.

Scientific Relevance

• Uterotonic Research: Cargutocin provides a stable model for studying oxytocin receptor activation and sustained uterine contraction.

• Endocrinology & Reproductive Biology: Useful in experiments on hormonal regulation of parturition and postpartum uterine recovery.

• Drug Discovery: Serves as a structural lead for the development of novel oxytocin analogues.

• Comparative Pharmacology: Enables direct comparison of receptor binding affinities, efficacy, and signal transduction mechanisms relative to oxytocin.

Advantages in Research

• Higher resistance to enzymatic breakdown than natural oxytocin.

• Provides consistent uterotonic response in isolated tissue and whole-animal studies.

• Useful for dose-response analysis in uterine receptor models.

• Manufactured under GMP-grade conditions, ensuring reproducibility across laboratory settings.

2. Product Specifications 

3. Mechanism of Action & Research Applications 

Mechanism of Action

Cargutocin acts as a selective agonist of the oxytocin receptor, a G-protein coupled receptor (GPCR) expressed primarily in the uterus and mammary gland. Upon binding to OXTR:

1. Gq protein coupling activates phospholipase C (PLC).

2. PLC hydrolyzes PIP2 into IP3 and DAG.

3. IP3 triggers Ca²? release from the sarcoplasmic reticulum, elevating intracellular calcium levels.

4. Increased calcium interacts with calmodulin, stimulating myosin light-chain kinase (MLCK), leading to smooth muscle contraction.

The net effect is sustained uterine contraction, with greater potency and duration compared to natural oxytocin.

Research Applications

1. Uterine Physiology Research

   • Studying molecular mechanisms of labor induction.

   • Investigating postpartum uterine recovery dynamics.

2. Endocrine and Reproductive Biology

   • Exploring hormonal regulation of fertility, lactation, and maternal bonding.

   • Understanding oxytocin receptor signaling pathways.

3. Comparative Pharmacology

   • Comparing oxytocin analogues for receptor affinity, efficacy, and metabolic stability.

   • Determining dose-response curves across mammalian uterine tissues.

4. Pharmacodynamics & Pharmacokinetics

   • Analyzing half-life, bioavailability, and degradation resistance relative to oxytocin.

5. Translational Research Value

   • Provides insights for developing long-acting uterotonics.

   • Offers preclinical data for maternal health therapeutics.

     

4. Side Effects (Research Reference) 

In preclinical and experimental research, the following effects may be observed:

• Dose-Dependent Uterine Hyperstimulation: High concentrations can lead to prolonged uterine contractions.

• Cardiovascular Effects: Potential transient changes in blood pressure or heart rate.

• Electrolyte Shifts: High-dose analogues may influence fluid balance due to oxytocin’s antidiuretic-like properties.

• Tissue Receptor Desensitization: Prolonged exposure may reduce receptor sensitivity over time.

• Solvent-Related Effects: Dependent on formulation and administration route in experimental models.

These findings are reported in laboratory research models and are not indicative of clinical safety or efficacy.

5. Disclaimer

For laboratory research use only. Not for human or veterinary use.

6. Keywords

• Cargutocin

• Cargutocin CAS 33605-67-3

• Oxytocin analogue research peptide

• Uterotonic agent peptide

• Oxytocin receptor agonist

• Reproductive biology peptide

• Uterine contraction research

• GMP supplier Cargutocin

• Endocrinology research peptide

• Laboratory use oxytocin analogue